Correction: Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from japan and south korea
- PMID: 38216292
- PMCID: PMC10806473
- DOI: 10.1136/rmdopen-2021-001629corr1
Correction: Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from japan and south korea
Erratum for
-
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.RMD Open. 2021 Jul;7(2):e001629. doi: 10.1136/rmdopen-2021-001629. RMD Open. 2021. PMID: 34215703 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources